



Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference

January 6, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year's 38th annual J.P. Morgan Healthcare Conference.

Mr. Bancel's presentation will take place on Monday, January 13, 2020 at 4:30 p.m. PT in the Colonial Room at The Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session will be available under "Events & Presentations" in the investors section of Moderna's website at <https://investors.modernatx.com/>. A replay of the webcast will be archived on Moderna's website for 30 days following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top employer by *Science* for the fifth year in a row. To learn more, visit www.modernatx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200106005539/en/>

Source: Moderna, Inc.

Investors:

Lavina Talukdar

Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com